Plasma Proteomic and Metabolomic Predictors of Vascular Disease in Treated HIV
HIV治疗者血管疾病的血浆蛋白质组学和代谢组学预测因子
基本信息
- 批准号:10331583
- 负责人:
- 金额:$ 78.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-20 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgeBasic ScienceBioinformaticsBiologicalBiological AssayBiological MarkersBloodBlood VesselsBlood coagulationCarnitineCatabolismClinicalClinical TrialsCohort StudiesConsensusCytomegalovirusDataDiseaseDisease OutcomeEducational workshopEnzyme-Linked Immunosorbent AssayEpidemiologyEtiologyEventGenderGeneral PopulationGoalsGonadal Steroid HormonesHIVHIV InfectionsHealth behaviorHeart failureImmunoglobulin GImmunologicsImmunologyIncidenceInflammationInflammatoryInterventionIntervention TrialIschemic StrokeKynurenineLinkMalignant NeoplasmsMediatingMenopausal StatusMetabolic PathwayMorbidity - disease rateMyocardial InfarctionNon-Insulin-Dependent Diabetes MellitusParticipantPathogenesisPathway interactionsPatternPhenotypePlasmaPostmenopauseProteinsProteomeProteomicsRecurrenceResearch PersonnelResourcesRiskSamplingSmokingStrokeSurrogate MarkersSystemSystems BiologyTimeTryptophanUnited States National Institutes of HealthValidationVascular DiseasesVeinsViralWomanadjudicateadvanced diseaseantiretroviral therapycis-malecohortcomorbiditydemographicsdesignexperiencehigh riskhormone therapyimmune activationimmunoregulationinflammatory markerinjection drug useinterestmenmetabolomemetabolomicsmicrobialmortalitymultidisciplinarymultiple chronic conditionsnew therapeutic targetnovelpredictive markerprotein metabolitesexsystemic inflammatory responsetransgender womentrendvenous thromboembolism
项目摘要
PROJECT SUMMARY/ABSTRACT
People with HIV (PWH) remain at higher risk for Type 1 myocardial infarction (T1MI), ischemic stroke, and
venous thromboembolism (VTE) than the general population despite antiretroviral therapy (ART)-mediated
viral suppression. Systemic inflammation persists in many PWH despite ART and predicts each of these
vascular events, but the optimal interventional targets remain unclear. To begin to address these issues, we
performed an initial case-cohort study of nearly 1,200 PWH within the CFAR Network of Integrated Clinical
Systems (CNICS) who were maintaining at least 1 year of ART-mediated viral suppression and identified
several plasma inflammatory markers – including surrogate markers of microbial translocation, CMV, and the
kynurenine pathway of tryptophan catabolism - that predicted increased risk of subsequent vascular events.
We also observed that women (particularly at post-menopausal ages) had higher levels of most inflammatory
markers than men, and trends suggesting that sex may modify the association between inflammation and
vascular events. This proposal will build upon these findings by nearly doubling the adjudicated vascular event
cases in our study (n=135 T1MI, n=74 ischemic strokes, and n=135 VTE). We will also assess the plasma
proteomic and metabolomic pathways most strongly predictive of each event type and explore the associations
between sex and plasma sex hormone levels and the pathways that predict vascular disease. Aim 1 will
assess the plasma proteomic pathways that most strongly predict T1MI, ischemic stroke, and VTE using the
most comprehensive plasma proteomic platform (SomaScan, targeting 7,000 proteins), and validating the top
hits with commercial ELISAs and by cross-validation in the VACS BC cohort. Aim 2 will assess the plasma
metabolomic predictors of these vascular events using an untargeted metabolomic approach, confirming top
hits with quantitative assays, and quantitative assessments of metabolites previously linked to vascular
disease (e.g., kynurenine and carnitine metabolic pathways). For both Aims 1 and 2, we will assess whether
the top immunologic hits that predict vascular disease outcomes are also increased in treated HIV compared to
HIV-uninfected controls matched for demographics and health-related behaviors in the SCOPE cohort. Aim 3
will assess the degree to which sex and plasma sex hormone levels are associated with the immunologic
pathways that predict vascular disease and whether these pathways vary by menopausal status and between
transgender women on gender-affirming hormonal therapy and cis-men. Lastly, we will explore whether sex
modifies the relationship between inflammatory pathways and vascular disease. These studies leverage a
multidisciplinary team with expertise in translational immunology, HIV pathogenesis, vascular disease,
metabolomics, epidemiology, and bioinformatics and will create a resource that can be leveraged by others to
assess predictors of other disease outcomes and/or add additional analytes. Collectively, these studies will
accelerate the identification of novel interventional targets to reduce multi-morbidity in treated HIV infection.
项目总结/摘要
HIV感染者(PWH)仍有较高的1型心肌梗死(T1 MI)、缺血性卒中和
尽管有抗逆转录病毒治疗(ART)介导,静脉血栓栓塞(VTE)仍比一般人群高
病毒抑制全身炎症持续存在于许多PWH尽管ART和预测每一个这些
血管事件,但最佳介入靶点仍不清楚。为了开始解决这些问题,我们
在CFAR综合临床网络内对近1,200名PWH进行了初步病例队列研究
维持至少1年ART介导的病毒抑制并确定
几种血浆炎症标志物-包括微生物易位的替代标志物,CMV,以及
色氨酸催化剂的犬尿氨酸途径-预测随后血管事件的风险增加。
我们还观察到,女性(特别是绝经后年龄的女性)的大多数炎症性细胞因子水平较高,
与男性相比,性别可能会改变炎症与
血管事件该提案将在这些发现的基础上,将裁定的血管事件增加近一倍
在我们的研究中,有135例T1 MI,74例缺血性卒中和135例VTE。我们还将评估血浆
蛋白质组学和代谢组学途径对每种事件类型的预测性最强,并探讨其相关性。
性和血浆性激素水平之间的联系以及预测血管疾病的途径。目标1将
评估血浆蛋白质组学途径,最强有力地预测T1 MI,缺血性卒中,和静脉血栓栓塞使用
最全面的血浆蛋白质组学平台(SomaScan,针对7,000种蛋白质),并验证
通过商业ELISA和VACS BC组群中的交叉验证的命中。目标2将评估血浆
使用非靶向代谢组学方法,这些血管事件的代谢组学预测因子,证实了
定量分析命中,以及先前与血管相关的代谢物的定量评估
疾病(例如,犬尿氨酸和肉毒碱代谢途径)。对于目标1和2,我们将评估
与对照组相比,治疗组中预测血管疾病结局的最高免疫学命中率也有所增加,
在SCOPE队列中,未感染HIV的对照组与人口统计学和健康相关行为相匹配。目标3
将评估性别和血浆性激素水平与免疫功能相关的程度。
预测血管疾病的途径,以及这些途径是否因绝经状态而异,
接受性别确认荷尔蒙疗法的变性妇女和顺性男子。最后,我们将探讨性是否
改变炎症途径和血管疾病之间的关系。这些研究利用了
多学科团队,在转化免疫学、HIV发病机制、血管疾病
代谢组学,流行病学和生物信息学,并将创建一个资源,可以利用他人,
评估其他疾病结局的预测因素和/或添加额外的分析物。这些研究将
加速确定新的干预靶点,以减少已治疗艾滋病毒感染的多重发病率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER W HUNT其他文献
PETER W HUNT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER W HUNT', 18)}}的其他基金
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection
治疗无症状 CMV 复制对 HIV 感染治疗者心血管风险的影响
- 批准号:
10715847 - 财政年份:2023
- 资助金额:
$ 78.89万 - 项目类别:
Assessing the Interrelationship Between Adipose Tissue Thermogenesis and Fibrosis in the Metabolic Health of People Living with HIV
评估艾滋病毒感染者代谢健康中脂肪组织产热与纤维化之间的相互关系
- 批准号:
10626188 - 财政年份:2022
- 资助金额:
$ 78.89万 - 项目类别:
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
巨细胞病毒 (CMV)、HIV 的肠道屏障和免疫功能障碍
- 批准号:
10177602 - 财政年份:2021
- 资助金额:
$ 78.89万 - 项目类别:
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
巨细胞病毒 (CMV)、HIV 的肠道屏障和免疫功能障碍
- 批准号:
10875189 - 财政年份:2021
- 资助金额:
$ 78.89万 - 项目类别:
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
巨细胞病毒 (CMV)、HIV 的肠道屏障和免疫功能障碍
- 批准号:
10372191 - 财政年份:2021
- 资助金额:
$ 78.89万 - 项目类别:
Cytomegalovirus (CMV), the gut barrier and immune dysfunction in HIV
巨细胞病毒 (CMV)、HIV 的肠道屏障和免疫功能障碍
- 批准号:
10578682 - 财政年份:2021
- 资助金额:
$ 78.89万 - 项目类别:
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection
治疗无症状 CMV 复制对 HIV 感染治疗者心血管风险的影响
- 批准号:
10242227 - 财政年份:2020
- 资助金额:
$ 78.89万 - 项目类别:
Persistent Functional Immune Defects in Treated HIV Infection
HIV感染治疗后持续存在功能性免疫缺陷
- 批准号:
9927206 - 财政年份:2020
- 资助金额:
$ 78.89万 - 项目类别:
Impact of Treating Asymptomatic CMV Replication on Cardiovascular Risk in Treated HIV Infection
治疗无症状 CMV 复制对 HIV 感染治疗者心血管风险的影响
- 批准号:
10449260 - 财政年份:2020
- 资助金额:
$ 78.89万 - 项目类别:
Persistent Functional Immune Defects in Treated HIV Infection
HIV感染治疗后持续存在功能性免疫缺陷
- 批准号:
10593968 - 财政年份:2020
- 资助金额:
$ 78.89万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 78.89万 - 项目类别:
Directed Grant